PerkinElmer Signs Exclusive Licensing Agreement with Max Planck Innovation for Silicon Photomultiplier (SiPM) Technology

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has entered into an exclusive agreement with Max Planck Innovation, the technology transfer organization of the Max Planck Society, for the licensing of its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology.

SiPM offers very high photon detection efficiencies, ultra-short response time and extremely low power consumption, making it applicable to a variety of low light level (LLL) applications. The technology was initially developed by a group led by Professor Boris Dolgoshein from the Moscow State Engineering Physics Institute (MEPhI), and further advanced through the cooperation of MEPhI and Professor Masahiro Teshima and Dr. Razmik Mirzoyan from the Max Planck Institute for Physics in Munich.

“This innovative SiPM technology from the Max Planck Society shows promise for several important human and environmental health applications,” said Michael Ersoni, vice president and general manager of PerkinElmer’s global detection business. “This licensing agreement complements and enhances PerkinElmer’s industry-leading portfolio of photon detection solutions. With access to Max Planck’s SiPM technology, PerkinElmer is further positioned to serve applications including positron emission tomography (PET) diagnostic scanning and a variety of analytical fluorescence applications.” PerkinElmer’s photon detection solutions include Si and InGaAs avalanche photodiodes (APDs) and PIN photodiodes for high performance applications as well as channel photomultipliers for molecular detection in analytical applications and clinical diagnostics.

“As a world leader in photon detection, PerkinElmer is an ideal industrial partner for licensing our SiPM technology. PerkinElmer has the experience and the global reach needed for introducing the SiPM technology to a variety of fast-moving markets to help advance both human and environmental health,” said Dr. Bernd Ctortecka, patent and license manager, Max Planck Innovation GmbH.